Applications of ultrahigh-speed long-range wide-field OCT in anterior eye diseases

超高速远距离宽视场OCT在眼前部疾病中的应用

基本信息

  • 批准号:
    10335273
  • 负责人:
  • 金额:
    $ 47.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-04-01 至 2023-01-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Optical coherence tomography (OCT) is uniquely able to achieve micron depth resolution while imaging a large 3-dimensional (3D) volume. This enables 3D imaging and precise measurements in the anterior segment of the eye, including the cornea, conjunctiva, sclera, anterior chamber, iris, and crystalline lens. Anterior segment OCT is already widely used in ophthalmology. But a number of high-impact applications were held back by limited speed, range, penetration, and disease-specific algorithms. Therefore the specific aims are to: (1) Develop ultrahigh performance OCT for anterior eye. A novel vertical-cavity surface-emitting laser (VCSEL) will be used to develop an OCT prototype with ultrahigh-speed, wide-field, long-range, and high- penetration. The high speed and penetration will allow blood vessel imaging (angiography) in iris tumors. The wide field and long range will enable accurate whole anterior-segment biometry from the apex of the cornea to the posterior surface of the crystalline lens, which will take intraocular lens (IOL) formulas and custom scleral contact lens design to a new level of accuracy. (2) Develop OCT angiography (OCTA) of iris tumors. Distinguishing between benign and malignant tumors, including deadly melanomas, is crucial for planning treatments that minimize damage to sensitive eye tissues and reduce the risk of metastasis. Increased vascularity marks malignant transformation in tumors. The proposed ultrahigh performance OCT prototype will enable OCTA in tumors with sufficient penetration to characterize both tumor vasculature and volume. Novel software algorithms will be used to suppress motion, projection, and shadow artifacts, segment tissue boundaries, and calculate quantitative vascular density and tortuosity measurements. The technology could be useful in the evaluation of tumor angiogenesis elsewhere. (3) Improve OCT-based IOL power formula. Previously we developed an OCT-based IOL formula that improved cataract surgery refractive outcome in post-myopic LASIK eyes. We now propose to further improve the OCT-based IOL formula so that it could improve refractive outcome in all cataract surgeries, and be used to select toric as well non-toric IOL. The long-range OCT can accurately measure the crystalline lens equatorial position to improve the prediction of IOL position, which is a crucial variable that currently limits the accuracy of IOL formulas. High-speed OCT together with ray-tracing will enable more accurate net corneal power and astigmatism measurements, especially in post-radial keratotomy and post-hyperopic LASIK eyes. (4) Improve scleral lens fitting with wide-field OCT. Scleral contact lens vaults over the cornea and offers an important nonsurgical option to restore comfort and vision to patients with irregular corneal shape or ocular surface inflammation. The primary limitation of scleral lens is the difficult trial-and-error fitting process. We will use wide-field OCT corneoscleral topography to improve the selection of the initial trial lens and design advanced radially asymmetric scleral lenses that are highly customized to the subject ocular surface.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David Huang其他文献

David Huang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David Huang', 18)}}的其他基金

Advanced transepithelial corneal collagen crosslinking
先进的跨上皮角膜胶原交联
  • 批准号:
    10741684
  • 财政年份:
    2023
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    8479117
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    8916743
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    10211838
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    8740482
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    10430080
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Functional and Structural Optical Coherence Tomography for Glaucoma
青光眼的功能性和结构性光学相干断层扫描
  • 批准号:
    9130226
  • 财政年份:
    2013
  • 资助金额:
    $ 47.13万
  • 项目类别:
Guiding the Treatment of Anterior Eye Disease with Optical Coherence Tomography
光学相干断层扫描指导眼前部疾病的治疗
  • 批准号:
    8531251
  • 财政年份:
    2008
  • 资助金额:
    $ 47.13万
  • 项目类别:
Guiding the Treatment of Anterior Eye Disease with Optical Coherence Tomography
光学相干断层扫描指导眼前部疾病的治疗
  • 批准号:
    8913974
  • 财政年份:
    2008
  • 资助金额:
    $ 47.13万
  • 项目类别:
Guiding the Treatment of Anterior Eye Disease with Optical Coherence Tomography
光学相干断层扫描指导眼前部疾病的治疗
  • 批准号:
    8324529
  • 财政年份:
    2008
  • 资助金额:
    $ 47.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 47.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了